πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12042543

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste h

Northwestern University Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042558

Method and formulation for improving roflumilast skin penetration lag time

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042487

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043620

Benzazole compounds and methods for making and using the compounds

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043660

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their u

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042510

Modulators of IRF4 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043833

Targeted compositions

ARBUTUS BIOPHARMA CORPORATION Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043843

Materials and methods for treatment of hemoglobinopathies

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043847

Compositions and methods for treating acne

The Regents of the University of California Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037616

Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

CRISPR THERAPEUTICS AG Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036234

Heparin conjugated to collagen-binding peptides for targeting to biological and synthetic

Northwestern University Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036243

BCMA CAR-T cells with enhanced activities

Allogene Therapeutics, Inc. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037618

PH20 polypeptide variants, formulations and uses thereof

HALOZYME, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036255

Bacteriophage compositions and methods for treatment of bacterial infections

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037411

Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugat

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037607

Methods of preparing hematopoietic progenitor cells in vitro

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12038433

Methods and apparatus for high-throughput screening for testing permeability and retention

The Board of Regents of the University of Texas System Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036198

Dosage forms and therapeutic uses of L-4-chlorokynurenine

VISTAGEN THERAPUETICS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036211

Nicorandil derivatives

UNICYCIVE THERAPEUTICS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036319

Polyvalent sting activating compositions and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036225

Use of ibezapolstat to promote microbiome health

Acurx Pharmaceuticals, Inc. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036256

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036288

Methods of using humanized FCΞ³R mice to assay Fc regions

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036269

Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocystei

The Board of Regents of the University of Texas System Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted